Please wait while the formulary information is being retrieved.
FIRMAGON (DEGARELIX ACETATE)
- Advanced prostatic carcinoma
- Firmagon Subcutaneous Solution
- Firmagon Kit With Diluent Syringe Subcutaneous Solution
- By Indication
120 mg subcutaneous solution
- Inject 240 mg as 2 equally divided injections by subcutaneous route once in the abdomen using 2 separate injection sites
kit with diluent syringe 120 mg subcutaneous solution
- Inject 240 mg as 2 equally divided injections by subcutaneous route once in the abdomen using 2 separate injection sites
kit with diluent syringe 80 mg subcutaneous solution
- Inject 80 mg by subcutaneous route every 28 days in the abdomen rotating injection sites
Advanced prostatic carcinoma
- Inject 80 mg by subcutaneous route once in the abdomen
- Inject 80 mg by subcutaneous route every 28 days in the abdomen rotating injection sites
- Inject 240 mg as 2 equally divided injections by subcutaneous route once in the abdomen using 2 separate injection sites
- natalizumab
- Tysabri
Contraindicated
- amiodarone
- amiodarone in dextrose,iso-osm
- artemether-lumefantrine
- Coartem
- Cordarone
- disopyramide
- dronedarone
- droperidol
- Geodon
- Multaq
- Nexterone
- Norpace
- Norpace Cr
- Orap
- Pacerone
- pimozide
- thioridazine
- ziprasidone HCl
- ziprasidone mesylate
Severe
Moderate
- Ablavar
- alfuzosin
- Anzemet
- Apokyn
- apomorphine
- arsenic trioxide
- Avelox
- Avelox Abc Pack
- Avelox In Nacl (iso-osmotic)
- bedaquiline
- Betapace
- Betapace Af
- Caprelsa
- Celexa
- Cipro
- Cipro In D5W
- Cipro Xr
- ciprofloxacin
- ciprofloxacin (mixture)
- ciprofloxacin in D5W
- citalopram
- clozapine
- Clozaril
- Complera
- crizotinib
- dasatinib
- Diskets
- dofetilide
- dolasetron
- Dolophine
- Edurant
- emtricitab-rilpivirine-tenofov
- eribulin
- escitalopram oxalate
- ezogabine
- Fareston
- Fazaclo
- gadofosveset trisodium
- Halaven
- Haldol
- Haldol Decanoate
- haloperidol
- haloperidol decanoate
- haloperidol lactate
- Invega
- Invega Sustenna
- Invirase
- Istodax
- Kaletra
- lapatinib
- Levaquin
- Levaquin In 5 % Dextrose
- levofloxacin
- levofloxacin in D5W
- Lexapro
- lopinavir-ritonavir
- methadone
- Methadone Intensol
- Methadose
- moxifloxacin
- moxifloxacin in NaCl (iso-osm)
- Nexavar
- nilotinib
- norfloxacin
- Noroxin
- Noxafil
- ondansetron
- ondansetron HCl
- ondansetron HCl (PF)
- paliperidone
- paliperidone palmitate
- pasireotide
- pazopanib
- posaconazole
- Potiga
- propafenone
- Qualaquin
- quetiapine
- quinine sulfate
- rilpivirine
- romidepsin
- Rythmol
- saquinavir mesylate
- Seroquel
- Seroquel Xr
- Signifor
- Sirturo
- sorafenib
- Sorine
- sotalol
- Sotalol Af
- Sprycel
- Tasigna
- telavancin
- tetrabenazine
- Tikosyn
- toremifene
- Trisenox
- Tykerb
- Uroxatral
- vandetanib
- vemurafenib
- Versacloz
- Vfend
- Vfend Iv
- Vibativ
- voriconazole
- Votrient
- Xalkori
- Xenazine
- Zelboraf
- Zofran
- Zofran Odt
- Zuplenz
- Pregnancy
Contraindicated
- Chronic heart failure
- Congenital long QT syndrome
- Hypokalemia
- Hypomagnesemia
- Prolonged QT interval
Severe
Moderate
- Disease of liver
- Osteopenia
FIRMAGON (DEGARELIX ACETATE)
- Advanced prostatic carcinoma
- None
- Abnormal hepatic function tests
- Fatigue
- Flushing
- Injection site sequelae
- Weight gain
More Frequent
Severe
Less Severe
- Hypertension
- Arthralgias
- Chills
- Constipation
- Diarrhea
- Dizziness
- Erectile dysfunction
- Fever
- General weakness
- Gynecomastia
- Headache disorder
- Hyperhidrosis
- Insomnia
- Nausea
- Night sweats
- Testicular atrophy
- Urinary tract infection
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Angioedema
- Osteopenia
- Prolonged QT interval
Less Severe
- Urticaria
Contraindicated
None
Severe Precaution
Degarelix
No safety and efficacy established.
- 1 Day – 18 Years
- No safety and efficacy established.
Management or Monitoring Precaution
None
Degarelix
- Severity Level:
X
- Additional Notes: Not indicated in women
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Degarelix
Not indicated for use in women
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Not indicated for use in women |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Advanced prostatic carcinoma | |
| C61 | Malignant neoplasm of prostate |
| 0-9 | A-Z |
|---|---|
| C61 | Malignant neoplasm of prostate |
Formulary Reference Tool